Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22069849 | 1.00 | GLA (0.47) | GLANR4A2HDAC3HDAC4HDAC1 | |
| SCHEMBL22070157 | 0.90 | GLA (0.46) | GLANR4A2HDAC3HDAC4HDAC1 | |
| SCHEMBL13203784 | 0.90 | GLA (0.46) | GLANR4A2HDAC3HDAC4HDAC1 | |
| SCHEMBL22309191 | 0.89 | GLA (0.45) | GLANR4A2HDAC3HDAC4HDAC1 | |
| SCHEMBL22069886 | 0.89 | GLA (0.45) | GLANR4A2HDAC3HDAC4HDAC1 | |
| SCHEMBL22069844 | 0.85 | GLA (0.42) | GLANR4A2HDAC3HDAC4HDAC1 | |
| SCHEMBL22309193 | 0.85 | GLA (0.42) | GLANR4A2HDAC3HDAC4HDAC1 | |
| SCHEMBL22070144 | 0.84 | GLA (0.52) | GLANR4A2CNR1CNR2ALDH1A1 | |
| SCHEMBL22070143 | 0.84 | GLA (0.52) | GLANR4A2CNR1CNR2ALDH1A1 | |
| SCHEMBL22345961 | 0.81 | GSK3B (0.40) | GLANR4A2HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| EP-3666787-B1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-02-21 | — | — | EP | disclosed |
| EP-4321523-A2 | HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-14 | — | — | EP | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| EP-3925668-A1 | HEMIASTERLIN DERIVATIVE HAVING CYSTEINE RESIDUE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020166600-A1 | HEMIASTERLIN DERIVATIVE HAVING CYSTEINE RESIDUE | 大日本住友製薬株式会社 | 2020-08-20 | — | — | WO | disclosed |
| WO-2020166613-A1 | AGENT FOR ELIMINATING PLURIPOTENT STEM CELLS | 大日本住友製薬株式会社 | 2020-08-20 | — | — | WO | disclosed |
| WO-2020166592-A1 | HEMIASTERLIN DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | 大日本住友製薬株式会社 | 2020-08-20 | — | — | WO | disclosed |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| EP-3666787-A1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-3666788-A1 | HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | POU5F1, POU2F1, POU2F2 | GLA 698/4885NR4A2 2510/4885HDAC3 944/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | GLA 1027/4885NR4A2 713/4885HDAC3 249/4885 |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | GLA 1027/4885NR4A2 713/4885HDAC3 249/4885 |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | FCGRT, QARS1, INHA | GLA 2903/4885NR4A2 1058/4885HDAC3 1197/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | GLA 2903/4885NR4A2 1058/4885HDAC3 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.